Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics, a Canadian biotech firm, is advancing cancer treatment by developing a novel targeted Radio-Immuno-Conjugate (RIC) in partnership with the multinational nuclear company Orano. Their innovative RIC, which leverages Defence’s proprietary Accum technology, aims to deliver radioactivity directly to cancer cells while minimizing damage to healthy tissue. This cutting-edge approach could revolutionize cancer therapy by utilizing Auger electron emitters, previously unused due to their limitations.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
